Imperial College London
Alternate

ProfessorMatthewPickering

Faculty of Medicine, Department of Immunology and Inflammation

Centre Director, Professor of Rheumatology
 
 
 
//

Contact

 

matthew.pickering Website

 
 
//

Assistant

 

Miss Claudia Rocchi +44 (0)20 3313 2315

 
//

Location

 

9N12Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Prendecki:2020:ckj/sfaa192,
author = {Prendecki, M and Clarke, C and Medjeral-Thomas, N and McAdoo, SP and Sandhu, E and Peters, JE and Thomas, DC and Willicombe, M and Botto, M and Pickering, MC},
doi = {ckj/sfaa192},
journal = {Clinical Kidney Journal},
pages = {889--896},
title = {Temporal changes in complement activation in haemodialysis patients with COVID-19 as a predictor of disease progression},
url = {http://dx.doi.org/10.1093/ckj/sfaa192},
volume = {13},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Complement activation may play a pathogenic role in patients with severe coronavirus disease 2019 (COVID-19) by contributing to tissue inflammation and microvascular thrombosis. Methods: Serial samples were collected from patients receiving maintenance haemodialysis (HD). Thirty-nine patients had confirmed COVID-19 and 10 patients had no evidence of COVID-19. Plasma C5a and C3a levels were measured using enzyme-linked immunosorbent assay. Results: We identified elevated levels of plasma C3a and C5a in HD patients with severe COVID-19 compared with controls. Serial sampling identified that C5a levels were elevated prior to clinical deterioration in patients who developed severe disease. C3a more closely mirrored both clinical and biochemical disease severity. Conclusions: Our findings suggest that activation of complement plays a role in the pathogenesis of COVID-19, leading to endothelial injury and lung damage. C5a may be an earlier biomarker of disease severity than conventional parameters such as C-reactive protein and this warrants further investigation in dedicated biomarker studies. Our data support the testing of complement inhibition as a therapeutic strategy for patients with severe COVID-19.
AU  - Prendecki,M
AU  - Clarke,C
AU  - Medjeral-Thomas,N
AU  - McAdoo,SP
AU  - Sandhu,E
AU  - Peters,JE
AU  - Thomas,DC
AU  - Willicombe,M
AU  - Botto,M
AU  - Pickering,MC
DO  - ckj/sfaa192
EP  - 896
PY  - 2020///
SN  - 2048-8505
SP  - 889
TI  - Temporal changes in complement activation in haemodialysis patients with COVID-19 as a predictor of disease progression
T2  - Clinical Kidney Journal
UR  - http://dx.doi.org/10.1093/ckj/sfaa192
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33123364
UR  - http://hdl.handle.net/10044/1/84071
VL  - 13
ER  -
Download